Tumor News and Research

RSS

City of Hope receives $3.7 million from CIRM to develop phase 1 glioblastoma trial

The California Institute for Regenerative Medicine board has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy.

30 Jun 2018

Study finds sex-based differences in genetic risk factors for developing gliomas

Glioma is the most common type of primary malignant brain tumor in the United States; glioblastoma being the most common type of glioma in adults.

29 Jun 2018

Modified natural killer cells may be new player in CAR-T immunotherapies

Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.

29 Jun 2018

Review discusses complexity of immune-suppressive mechanisms in tumor milieu of cancers

Cancers control immune systems and evade immune detection using mediators consisting of immune checkpoint molecules and cellular systems associated with immune suppression.

29 Jun 2018

Penn cancer researchers reveal secrets of 'hot' and 'cold' pancreatic tumors

So-called "hot" tumors filled with T cells are often considered to be more sensitive to immunotherapy compared to "cold" tumors with fewer T cells, but a clear demonstration of why has eluded cancer biologists--until now.

29 Jun 2018

Study shows precision medicine improves outcomes in pancreatic cancer patients

A study published today by the Pancreatic Cancer Action Network, Perthera, Inc., and colleagues in the AACR journal Clinical Cancer Research found for the first time that precision medicine can improve outcomes and provide clinically meaningful information to pancreatic cancer patients.

28 Jun 2018

Genetic biomarker can help predict survival outcomes in patients with certain gliomas

A DNA-level biomarker (MGMT promoter methylation) can be used to help predict survival outcomes in patients with high-risk, low-grade gliomas, according to a new study conducted through the NRG Oncology/RTOG collaborative clinical trials group and led by scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

28 Jun 2018

New test predicts whether bladder cancer will become invasive

A new study has shown that a simple, new diagnostic test helps predict whether early stage bladder cancer will become invasive.

28 Jun 2018

DNA methylation predicts survival outcome in patients with glioma

A new study has shown that survival rates among patients with glioma double if the tumor carries a methylated MGMT gene.

28 Jun 2018

A small molecule can inhibit chemotherapy resistance of certain tumors

A team of researchers from the CNRS and Université Nice Sophia Antipolis has just shown that a small molecule called methiothepin can inhibit the chemotherapy resistance of certain tumors.

28 Jun 2018

Researchers show how mutant CALR protein triggers cancer

Researchers at Juntendo University report in the journal Leukemia how mutants of the protein calreticulin lead to molecular mechanisms triggering myeloproliferative neoplasms, which can cause cancer. The findings may lead to the development of novel therapies for certain types of blood cancer.

28 Jun 2018

Researchers target K17 in the fight against pancreatic cancer

Keratin 17 (K17), a protein that promotes cancer, may prove to be a key target gene in the battle against pancreatic cancer.

28 Jun 2018

Researchers scale up fluorescence imaging technique to analyze larger areas

Researchers have scaled up a powerful fluorescence imaging technique used to study biological processes on the cellular level. Previously limited to samples just millimeters in area, the expanded approach can analyze samples with areas up to 4 square centimeters.

27 Jun 2018

Salk Institute scientists receive funding for cancer research

Salk Institute scientists Ronald Evans, Diana Hargreaves, Tony Hunter, Graham McVicker and Geoffrey Wahl are among the first wave of researchers to receive funding from Padres Pedal the Cause, one of one of the largest stand-alone cancer fundraising events in San Diego.

27 Jun 2018

New avenue for cancer treatment opens when one drug fails

A new class of cancer drugs – called CDK4/6 inhibitors -- recently approved to treat breast cancer can stunt the cancer's growth and replication.

27 Jun 2018

Polio virus could help brain cancer patients

According to researchers genetically altered poliovirus strains could help some patients of brain cancer. A team of researchers from Duke University in Durham, North Carolina, used modified polio virus strains in small groups of patients who had glioblastoma – a particularly deadly form of brain cancer. In these patients standard treatments have failed say the researchers and this novel therapy could help.

27 Jun 2018

Study shows benefits, safety of long-lasting radionuclide therapy for patients with advanced NETs

A first-in-human study presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging demonstrates the benefits and safety of a new, long-lasting type of radionuclide therapy for patients with advanced, metastatic neuroendocrine tumors.

26 Jun 2018

AI could improve clinical diagnosis and treatment of prostate cancer

Researchers in Sweden have shown how data-driven AI could contribute to a better understanding of how prostate cancer develops, and even improve clinical diagnosis and treatment of the disease.

26 Jun 2018

Study finds byproduct of common prostate cancer drug can stimulate growth of tumor cells

A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic. The findings may provide important information for identifying which patients potentially fare better when treated with an alternate therapy.

26 Jun 2018

Phase 1 clinical trial of poliovirus therapy shows long-term survival benefit for recurrent glioblastoma

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial.

26 Jun 2018